WEST LAFAYETTE, Ind., March 27, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small
molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that eight posters will be
presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annual Meeting 2017 to be held in
Washington, DC, April 1 - 5, 2017.
Key presentations during the meeting include a late-breaking poster presentation of new research from investigators and faculty
at the Purdue University Center for Drug Discovery on the application of Endocyte's SMDC technology in a chimeric antigen receptor
(CAR) therapy setting. Additionally, the company will present several posters with preclinical data relating to Endocyte’s SMDC
technology, including developments in combination therapies and novel proPBD warheads.
The presentation materials will be available on Endocyte’s website following presentation at the conference.
Presentations are as follows:
| Abstract #: |
|
|
2057 |
| Title: |
|
|
Evaluation of anti-tumor efficacy of EC1456 in
low-passage and pre-treated patient-derived xenograft models of triple-negative breast cancer |
| When: |
|
|
Monday, April 3, 1 p.m. – 5 p.m. CDT |
| Session Title: |
|
|
Drug Resistance: Other Topics |
| Location: |
|
|
Halls A-C, Poster Section 3 |
| |
|
|
|
| |
|
|
|
| Abstract #: |
|
|
2133 |
| Title: |
|
|
Pre-clinical studies of EC2629, a highly potent FR
targeted DNA crosslinking agent |
| When: |
|
|
Monday, April 3, 1 p.m. – 5 p.m. CDT |
| Session Title: |
|
|
New Targets 2 |
| Location: |
|
|
Halls A-C, Poster Section 6 |
| |
|
|
|
| |
|
|
|
| Abstract #: |
|
|
LB-187 |
| Title: |
|
|
New methods for controlling CAR T-cell mediated cytokine
storms |
| When: |
|
|
Tuesday, April 4, 8 a.m. – 12 p.m. CDT |
| Session Title: |
|
|
Late-Breaking Research: Immunology |
| Location: |
|
|
Poster Section 35 |
| |
|
|
|
| |
|
|
|
| Abstract #: |
|
|
3670 |
| Title: |
|
|
Treatment of epithelial ovarian cancer with folate
receptor (α/β) targeted chemotherapy is enhanced by CTLA-4 blockage: Learning from animal models |
| When: |
|
|
Tuesday, April 4, 8 a.m. – 12 p.m. CDT |
| Session Title: |
|
|
Dendritic Cells as Critical Immune Targets |
| Location: |
|
|
Halls A-C, Poster Section 27 |
| |
|
|
|
| |
|
|
|
| Abstract #: |
|
|
3228 |
| Title: |
|
|
Development and characterization of in vitro assays to
detect and quantitate tubulysin B hydrazide in biological samples |
| When: |
|
|
Tuesday, April 4, 8 a.m. – 12 p.m. CDT |
| Session Title: |
|
|
Novel Molecular Targets 2 |
| Location: |
|
|
Halls A-C, Poster Section 8 |
| |
|
|
|
| |
|
|
|
| Abstract #: |
|
|
4017 |
| Title: |
|
|
Development and application of an
immunohistochemistry-based assay for evaluating functional and accessible folate receptor expression in vivo |
| When: |
|
|
Tuesday, April 4, 1 p.m. – 5 p.m. CDT |
| Session Title: |
|
|
Assay Technology |
| Location: |
|
|
Halls A-C, Poster Section 1 |
| |
|
|
|
| |
|
|
|
| Abstract #: |
|
|
4574 |
| Title: |
|
|
Combinatorial strategies of folate receptor-targeted
chemotherapy guided by improved understanding of tumor microenvironment and immunomodulation |
| When: |
|
|
Tuesday, April 4, 1 p.m. – 5 p.m. CDT |
| Session Title: |
|
|
Clinical Immunotherapy, Viruses, and bacteria |
| Location: |
|
|
Halls A-C, Poster Section 25 |
| |
|
|
|
| |
|
|
|
| Abstract #: |
|
|
5147 |
| Title: |
|
|
Novel warheads for targeted therapies of cancer: The
concept and design of proPBDs |
| When: |
|
|
Wednesday, April 5, 8 a.m. – 12 p.m. CDT |
| Session Title: |
|
|
Novel Drug Delivery Technology |
| Location: |
|
|
Halls A-C, Poster Section 5 |
About Endocyte's SMDC Bi-Specific Adaptors
Endocyte's SMDC bi-specific adaptors represent a novel approach that makes possible the engineering of a single universal CAR
T-cell, designed to bind with high affinity to fluorescein isothiocyanate (FITC). This universal CAR T-cell can be
specifically directed to cancer cells through the administration of a tumor targeted FITC-containing SMDC, known as a bi-specific
adaptor that acts to bridge the universal CAR T-cell with the cancer cells to cause localized T-cell activation. This
approach has been shown pre-clinically to address three key CAR T-cell issues by: (i) avoiding hyper-activation of CAR T-cells
leading to a cytokine storm, (ii) enabling termination of CAR T-cell activity upon eradication of the tumor, and (iii) potentially
enabling elimination of all cancer cells in heterogeneous solid tumors. In March 2017, Endocyte entered into a research
collaboration with Seattle Children's Research Institute and Dr. Michael Jensen for the development of Endocyte's SMDC platform in
the chimeric antigen receptor T-cell (CAR T-cell) immunotherapy setting through the use of Endocyte's proprietary SMDC bi-specific
adaptor molecules.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other
serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging
agents for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased
cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active
drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug
alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy
and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte's website at
www.endocyte.com.
Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com
